Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.

Abstract: The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor-cells.

Abstract: The invention relates to pyridines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor cells.

Abstract: The invention relates to a method for producing biperiden by reacting exo-1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone with a phenylmagnesium compound. According to the invention, exo-1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone can be obtained by reacting the exo-ether of enol silylene of formula (IV) with a compound of N-methylenepiperidinium.

Abstract: Process for the preparation of heat-stable, antimony-free polyesters of neutral color and the products which can be prepared by this process A process for the preparation of heat-stable, antimony-free polyesters of neutral color by esterification of aromatic dicarboxylic acids or transesterification of lower aliphatic esters of aromatic dicarboxylic acids with aliphatic diols and subsequent polycondensation in which a possible transesterification is carried out in the presence of 20 to 120 ppm, based on the catalyst metal, of a transesterification catalyst, after the esterification or transesterification has ended, phosphoric acid, phosphorous acid and/or phosphonic acids or a derivative thereof are added to the esterification or transesterification batch as a completing agent in an amount which is 100% of the amount equivalent to the transesterification catalyst employed and up to 99% of the amount equivalent to the cobalt to be employed, up to 80 ppm of cobalt in the form of a cobalt compound are then adde

Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.

Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S.

Abstract: The invention relates to a method for the production of biperiden by reacting an exo/endo mixture of 1-(bicyclo[2.2.1.]hept-5-en-2-yl) 3-piperidino-1-propanone with a phenyl magnesium compound, wherein the exo/endo ratio of 1-(bicylo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone is at least 4.5:1.

Abstract: The invention relates to a method for the production of biperiden by reacting an exo/endo mixture of 1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone with a phenyl magnesium compound to form an isomer mixture of 1-(bi-cyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-piperidino-1-propanol, whereby biperiden is obtained therefrom by conversion of said mixture into corresponding hydrochloride, isolation of said hydrochloride, reconversion to the free base and crystallization of said biperiden.

Abstract: A dermal or transdermal therapeutic system comprising a sheet-like substrate or reservoir containing readily volatile auxiliary agents or active agents, which substrate or reservoir is covered on one of its sides with a backing layer impermeable to the ingredients and on the opposite side with a detachable, likewise impermeable protective layer to prevent loss of ingredients during prolonged storage, is characterized in that both the backing layer and the protective layer are made of plastic film which is on both sides with vapour-deposited metal

Abstract: A dispersion powder composition based on water-insoluble polymers with particularly low water absorption comprises, based on the total weight of the polymer, an amount in the range from 0.1 to 30% by weight of at least one carboxylic ester whose acid component has at least 6 carbon atoms and whose alcohol component is a polyhydroxy compound, preferably glycerol, diglycerol, or triglycerol. This is prepared by mixing polymer and protective colloid with the carboxylic ester to prepare a dispersion and then, where appropriate, drying this with simultaneous admixing of an anticaking agent, and gives good results when used for modifying wallpaper pastes, mortars, or concrete.

Abstract: Disclosed are therapeutic compounds having the formula: (R)j—(CORE MOIETY), including resolved enantiomers, diastereomers, hydrates, salts, solvates or mixtures thereof where j is an integer from one to three. The core moiety is a bicyclic ring structure having at least one heterocyclic ring that contains five to six ring atoms and up to two nitrogen heteroatoms. R is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C1-6 alkyl or C1-6 alkenyl, and at least one R has the formula I: n is an integer from 1 to 20, at least one of X or Y is —OH. Another of X or Y, which is not —OH, is hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2—or (CH3)2—CH2—, and each W1, W2, and W3 is independently hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2— or (CH3)2—CH2—.

Abstract: Novel pyridopyrimidine-based compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.

Abstract: A method for providing an end user patient with the ability to purchase health foods and the like pre-approved by the health care provider comprising the following steps: (a) providing a website comprising a virtual storefront created and populated by a health care provider whereby the patient can select and order health related non-prescription ingestibles; (b) facilitating the payment of the ingestibles by the patient according to payment options selected by the health care provider; and (c) facilitating the delivery of the ingestibles to the end user patient according to payment options selected by the health care provider.

Abstract: The invention is directed to thiazolidinones and the use thereof to inhibit phospholipase D (PLD) activity. The invention further relates to methods of treating cancer and inflammatory diseases using thiazolidinones.

Abstract: An apparatus is provided for dissipating heat from an electronic component, such as a processor, that is mounted in a conductive enclosure and for shielding electromagnetic radiation generated by the electronic component. The apparatus includes a heat sink that is configured to be mounted to a surface of the electronic component. The apparatus also includes a conductor connected to the heat sink. The conductor is configured to provide electrical contact between the heat sink and a surface of the conductive enclosure. Accordingly, the apparatus at least partially shields the electromagnetic radiation generated by the electronic component. A corresponding method is also provided.

Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.

Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.

Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.